RecruitingNCT05850689
Lumateperone or placebo added to antidepressant treatment for major depression
About this title
Read the official source — NCT05850689This study evaluates the safety and effectiveness of Lumateperone for people with depression.
Medication studyAges 18–65Multiple countries
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Lumateperone for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Huntsville and 68 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 2, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 470
- Sponsor
- Intra-Cellular Therapies, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Bulgaria, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05850689
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Recruitment & locations
RecruitingHuntsville, United States · Pico Rivera, United States · Farmington, United States
56 more locations
- Clermont, United States
- Hialeah, United States
- Miami, United States
- Tampa, United States
- Atlanta, United States
- Decatur, United States
- Kansas City, United States
- Overland Park, United States
- Methuen, United States
- O'Fallon, United States
- Toms River, United States
- Brooklyn, United States
- New York, United States
- Avon Lake, United States
- Cincinnati, United States
- Columbus, United States
- Philadelphia, United States
- Houston, United States
- Mansfield, United States
- Richardson, United States
- Bellevue, United States
- Cherven Bryag, Bulgaria
- Kardzhali, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Stara Zagora, Bulgaria
- Varna, Bulgaria
- Douai, France
- Nantes, France
- Nîmes, France
- Paris, France
- Poitiers, France
- Ahmedabad, India
- Ajmer, India
- Bārāmati, India
- Bikaner, India
- Chandigarh, India
- Guwahati, India
- Kolhāpur, India
- Nagpur, India
- Palsāna, India
- Pune, India
- Rajkot, India
- Wardha, India
- Kaunas, Lithuania
- Ziegzdriai, Lithuania
- Belgrade, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Barcelona, Spain
- Madrid, Spain
- Sabadell, Spain
- Zamora, Spain
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Lumateperone for people with depression.
Who is behind this study?
The study sponsor is Intra-Cellular Therapies, Inc.
Does this study involve medication?
Yes. The study involves medication, including Lumateperone and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
